News

Intestinal hereditary angioedema (HAE) should be considered as a possible cause of abdominal pain, even in patients with normal C1 inhibitor protein levels, suggests a case report study that described a woman with HAE being misdiagnosed with infectious colitis. The case study, “Wolf in the sheep’s clothing: intestinal angioedema mimicking…

Attune Pharmaceuticals’ ATN-249, an investigational kallikrein inhibitor for the prevention of swelling attacks in hereditary angioedema (HAE) patients, was found generally safe and well-tolerated in a Phase 1 clinical trial with healthy volunteers, the company announced. Findings from this first-in-human trial (ACTRN12618000430235) were also presented during the recent Western Society…

Physicians in Canada need better education about the multiple biological assays used to diagnose hereditary angioedema caused by C1 inhibitor deficiency (C1-INH-HAE), which will increase their confidence and access to relevant tests, a study shows. The study, “The diagnosis of hereditary angioedema with C1 inhibitor deficiency: a survey…

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…